Shay Capital’s Nektar Therapeutics NKTR Stock Holding History

Shay Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,480	Closed	-$328K	–	391
2024 Q4	$328K	Sell	23,480 -82,872	-78%	-$1.46M	0.05%	220
2024 Q3	$2.07M	Sell	106,352 -16,340	-13%	-$311K	0.29%	56
2024 Q2	$2.28M	Sell	122,692 -15,953	-12%	-$336K	0.32%	58
2024 Q1	$1.94M	Buy	+138,645	New	+$1.45M	0.3%	58

Other funds holding NKTR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Shay Capital's NKTR Position: Q1 2025 in Review

Shay Capital sold out of Nektar Therapeutics (NKTR) in Q1 2025, closing a stake of 23,480 shares — an estimated $328K sold.

Shay Capital first reported a position in NKTR in Q1 2024 and held it in 4 quarters. The position peaked at $2.28M in Q2 2024. 154 funds tracked by Wall St. Rank hold NKTR as of Q1 2025.

Shay Capital reported no remaining Nektar Therapeutics position as of Q1 2025 after selling out during the quarter.
Shay Capital sold 23,480 Nektar Therapeutics shares in Q1 2025, an estimated $328K.
Shay Capital first reported a position in Nektar Therapeutics in Q1 2024 and held it in 4 quarters.
Shay Capital's Nektar Therapeutics position peaked at $2.28M in Q2 2024.
154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2025.

Based on Shay Capital's 13F filing for Q1 2025, filed 15 May 2025.